Douglas Treco, Ph.D.
President and Chief Executive Officer, and Co-Founder
Doug has been Chief Executive Officer of Ra Pharma® since he co-founded the Company in June 2008, and serves on the Company’s Board of Directors. He was an Entrepreneur-in-Residence at Morgenthaler Ventures from January 2008 to May 2014. In 1988, Doug co-founded Transkaryotic Therapies Inc., or TKT, a multi-platform biopharmaceutical company developing protein and gene therapy products, which was acquired by Shire Pharmaceuticals Group plc. He was a Visiting Scientist in the Department of Molecular Biology at Massachusetts General Hospital and a Lecturer in Genetics at Harvard Medical School from 2004 to 2007. Doug received his Ph.D. in Biochemistry and Molecular Biology from the State University of New York, Stony Brook, and performed postdoctoral studies at the Salk Institute for Biological Studies and Massachusetts General Hospital.
Executive Vice President and Chief Financial Officer
David has served as Executive Vice President and Chief Financial Officer since January 2016. Before joining Ra Pharma, he served as a member of the senior management team of Tetraphase Pharmaceuticals, Inc., a biotechnology company, from its inception in 2006 through 2015, including serving as Senior Vice President and Chief Financial Officer from 2010 to 2015. From 1999 to 2005, David served as the Chief Financial Officer of PharMetrics Inc., a pharmacy and medical claims data informatics company. Prior to joining PharMetrics, David served as Vice President and Chief Financial Officer of ProScript from 1996 to 1999. David has more than 20 years of finance and executive leadership experience and serves on the Board of Directors of Nightstar Therapeutics plc (NASDAQ: NITE). He is a member of the American Institute of CPAs and is a Certified Public Accountant in the Commonwealth of Massachusetts. David received his B.S. in Business Administration from Northeastern University and an M.S. in Taxation from Bentley University.
Ramin Farzaneh-Far, M.D.
Chief Medical Officer
Ramin joined Ra Pharma in July 2016 as Chief Medical Officer. During 2015 and 2016, he served as the Vice President of Medical Research at Akebia Therapeutics, Inc. From 2012 until he joined Akebia, Ramin served as the Director of Clinical Research at Gilead Sciences, Inc., where he led the clinical development of multiple assets in the cardiovascular therapeutic area. Ramin held various academic faculty positions at the University of California, San Francisco (UCSF), and the University of Texas Southwestern Medical Center from 2009 to 2012. He completed his internal medicine residency at Brigham & Women’s Hospital in Boston, and trained in cardiovascular medicine at UCSF. Ramin received his B.A. and M.A. degrees in Immunology from the University of Cambridge, a Medical Degree from University College London, and an MAS in Clinical Research from UCSF.
Simon Read, Ph.D.
Chief Scientific Officer
Simon has been Chief Scientific Officer at Ra Pharma since April 2016. Prior to joining the company, he served as Vice President and Head of the Innovative Medicines Unit (IMU) at Grünenthal GmbH, a pharmaceutical company headquartered in Aachen, Germany from 2014 to 2016. Prior to that, Simon served as Vice President and Head of Global Biomedical Sciences at Grünenthal GmbH from 2011 to 2014. Before joining Grünenthal, he was the Director, Experimental Medicine and Biomarkers, Immunology with Roche Products/Genentech Inc. from 2008 to 2011. Simon has been a member of the Medical Research Council and Association of British Pharmaceutical Industry Steering Committee for the UK’s foremost Immunology Consortium since 2012. He has been a member of the Boston Children’s Hospital Technology Development Fund steering group since 2016. Simon received his B.Sc. in Physiology from University of Manchester, a M.Sc. from University of Southampton and a Ph.D. from University of Hertfordshire.
John C. King
Chief Commercial Officer
John joined Ra Pharma as Chief Commercial Officer in April 2018, bringing more than 20 years of senior, global, commercial leadership experience within the biotechnology rare disease space. Prior to joining the company, John was Vice President, U.S. Neurology Business Unit at Alexion Pharmaceuticals where he was responsible for building and leading the team that launched Soliris® (eculizumab) for gMG. At Alexion, he also served as Vice President, Head of Global LAL-D Franchise and Vice President, Head of Global PNH Franchise. Before joining Alexion in 2009, John served in commercial roles of increasing responsibility at Wyeth Pharmaceuticals, including Product Director of Enbrel® (etanercept). He began his career at Ernst & Young LLP. John obtained his B.S. in Business Logistics and MBA from Pennsylvania State University.
Alonso Ricardo, Ph.D.
Chief Technology and Innovation Officer and Head of Research
Alonso joined Ra Pharma in 2010 and has held a variety of roles with increasing responsibility. He received a Ph.D. in Chemistry from the University of Florida working under the supervision of Professor Steven A. Benner. Following graduation, Alonso joined the faculty of the Universidad de los Andes in Bogota, Colombia where he performed research in peptide macrocyclization and bioorganic chemistry. In 2006, he became an HHMI Research Associate with Professor Jack W. Szostak, working in synthetic biology at Harvard University and the Massachusetts General Hospital.
Senior Vice President, Regulatory, Quality, and Government Affairs
Peter joined Ra Pharma in November 2018 as Senior Vice President, Regulatory, Quality, and Government Affairs, bringing over 19 years of experience in the development, approval, and launch of pharmaceuticals and biologics. Prior to joining Ra Pharma, Peter served as Senior Vice President, Regulatory Affairs and Quality Assurance at Melinta Therapeutics. Prior to joining Melinta in 2014, Peter served as Vice President, Global Regulatory Affairs at Dendreon Corporation, where he was responsible for oversight of EMA approval of PROVENGE® for the treatment of prostate cancer. From 2009 to 2012, Peter served as Vice President, Global Regulatory Affairs at Merck KGaA/EMD Serono, providing regulatory guidance for the Company’s immunology, oncology, and neurodegenerative disease development portfolio. He began his career as a research scientist at Pharmacia & Upjohn and was later responsible for the global registration of Zyvox® for the treatment of drug-resistant bacterial infections at Pfizer. Mr. DiRoma holds a B.S. in Chemistry and Biology from the University of South Florida.
Senior Vice President, Technical Operations
Joe joined Ra Pharma in July 2019 as Senior Vice President, Technical Operations, bringing over 20 years of industry experience. Prior to joining the Company, Joe served as Senior Vice President, Global Technical Operations for Aegerion Pharmaceuticals, a Novelion Therapeutics Company, where he was responsible for ensuring patient supply for two globally approved commercial products, JUXTAPID® (lomitapide) and MYALEPT® (metreleptin), while leading all facets of Chemistry, Manufacturing, and Control (CMC), Supply Chain, Quality Assurance, Patient/Hub Services, and Program Management. Before Aegerion, he served as Vice President, Technical Operations at ZIOPHARM Oncology. His earlier career included roles of increasing responsibility at Otsuka Pharmaceuticals, Antigenics (now Agenus), Acusphere, and Dyax (now Shire). Joe obtained his B.S. in Engineering from Miami University and his M.B.A. from Boston University.